CJC-1295 No DAC Peptide: Modified GRF 1-29, Evidence, Risks, and Safer Questions to Ask

CJC-1295 no DAC is a short-acting growth hormone-releasing hormone analog often called Modified GRF 1-29. It is studied for signaling the pituitary gland to release growth hormone, but it is not FDA-approved for human treatment. Published human evidence is stronger for CJC-1295 with DAC than for no-DAC versions.

What is CJC-1295 no DAC?

CJC-1295 no DAC is a research name for a short-acting peptide related to growth hormone-releasing hormone, or GHRH. It is often called Modified GRF 1-29 because it is based on the active 1-29 fragment of GHRH, with changes meant to improve stability.

Why it is often called Modified GRF 1-29

Natural GHRH is a hormone made in the brain that tells the pituitary gland to release growth hormone. Modified GRF 1-29 is a lab-made version of the active GHRH fragment, discussed in peptide research as a GHRH analog or growth hormone secretagogue.

How it relates to growth hormone-releasing hormone

A GHRH analog is designed to act at the GHRH receptor on somatotroph cells in the pituitary gland. That receptor signal can increase growth hormone release, which can then affect insulin-like growth factor 1, or IGF-1, mainly through the liver and other tissues 2.

Why naming can be confusing for patients

The names are confusing because “CJC-1295” is often used online for both the long-acting DAC form and the short-acting no-DAC form. The DAC form is the one in the main published human CJC-1295 trial; no-DAC discussions often rely on mechanism, related GHRH research, and non-clinical sources rather than direct human outcome trials 1.

What quick facts should patients know about CJC-1295 no DAC?

CJC-1295 no DAC is best understood as an investigational peptide discussed for growth hormone signaling. The key safety point is that research-use-only products are not intended for self-treatment.

• CJC-1295 no DAC is not an FDA-approved medication for human treatment.
• It is not a steroid. It is discussed as a GHRH analog, which is a type of growth hormone secretagogue.
• Human outcome evidence for the no-DAC form is limited; GH and IGF-1 changes are biomarkers, not proven anti-aging outcomes.
• Most schedules described online are not FDA-approved treatment regimens.
• Chia does not list CJC-1295 no DAC as a current treatment.

How does CJC-1295 no DAC work in the growth hormone pathway?

Growth hormone-releasing hormone works like a signal from the brain to the pituitary gland. CJC-1295 no DAC is discussed as a short-acting version of that signal, but signaling is not the same as proven clinical benefit.

The GHRH receptor and the pituitary gland

The pituitary gland contains somatotroph cells, which can release growth hormone when the GHRH receptor is activated. This is different from taking synthetic human growth hormone, because a secretagogue asks the gland to release the body’s own hormone rather than adding growth hormone directly 2.

Growth hormone and IGF-1 signaling

Growth hormone can raise IGF-1, a downstream hormone used as a marker of GH activity. In the 2006 CJC-1295 with DAC study, researchers reported dose-related increases in growth hormone and IGF-1 after a single subcutaneous administration, with IGF-1 increases lasting longer than growth hormone peaks 1.

Why secretagogues are different from injecting synthetic human growth hormone

Synthetic human growth hormone products have FDA-approved uses for specific diagnoses, such as growth hormone deficiency and some growth disorders, and their labels include important contraindications and warnings 3. A GHRH analog or secretagogue is a different approach, with different evidence and risk questions.

What is the difference between CJC-1295 with DAC and CJC-1295 no DAC?

Drug Affinity Complex is the main difference. DAC was designed to let CJC-1295 bind albumin in the blood, which makes the signal last much longer than short-acting GHRH fragments 1.

Because the strongest published CJC-1295 human evidence involved the DAC-modified form, it should not be automatically applied to CJC-1295 no DAC. That distinction matters when online articles claim benefits for “CJC-1295” without saying which form was studied.

What does the human evidence actually show?

Human evidence for CJC-1295 is mostly biomarker evidence, not proof of anti-aging, recovery, sleep, or body-composition outcomes. The best-known study tested CJC-1295 with DAC, not the no-DAC version.

What the 2006 CJC-1295 study found about GH and IGF-1

In a randomized human study published in 2006, Teichman and colleagues studied single and repeated subcutaneous doses of CJC-1295 with DAC in healthy adults. The study reported dose-dependent increases in growth hormone and IGF-1, with no serious adverse events reported in that small study 1.

Why biomarker changes are not proven anti-aging benefits

Growth hormone and IGF-1 are biomarkers. A biomarker can show that a pathway moved, but it does not prove that a person will sleep better, recover faster, gain muscle, lose fat, or live longer. Reviews of peptide drugs show that peptide medicines can be powerful, but each peptide needs its own evidence for each use 4.

What is known from related GHRH analog research

Tesamorelin, sold under the brand name Egrifta SV, is a different GHRH analog with an FDA-approved indication to reduce excess abdominal fat in adults with HIV and lipodystrophy. Its label also lists risks, including glucose intolerance, fluid retention, injection-site reactions, and warnings about active malignancy 5. Approval of tesamorelin does not establish safety or effectiveness for CJC-1295 no DAC.

Evidence gaps for CJC-1295 no DAC specifically

For CJC-1295 no DAC, the honest answer is that direct human outcome evidence is thin. Most claims about longevity, body composition, recovery, or sleep are based on pathway logic, related compounds, or online practice patterns rather than large human trials of the no-DAC peptide.

What are the possible downsides and safety concerns?

Safety concerns include local reactions, headache, diarrhea, fluid-related symptoms, glucose questions, and uncertainty about long-term effects. Benefits should not be weighed without these risks.

Reported events in CJC-1295 research

In the 2006 CJC-1295 with DAC study, reported adverse events included generally mild events such as injection-site reactions, headache, and diarrhea 1. That does not prove long-term safety, especially for different forms, different routes, different doses, or combination use.

Why GH and IGF-1 changes may matter

The GH and IGF-1 pathway can affect glucose handling, fluid balance, soft tissue symptoms, and joint or nerve symptoms. FDA-approved growth hormone labels warn about issues such as glucose intolerance, intracranial hypertension, fluid retention, and use in certain serious illnesses or active cancer settings 3.

Why peptide purity, route, and compounding quality matter

Peptides bought as “research chemicals” may not have the same safeguards as prescribed medication from a licensed source. FDA has noted that some bulk substances used in compounding may present significant safety risks, and route, sterility, impurities, and dose accuracy can all matter 6.

FDA safety concerns for some growth hormone secretagogue peptides

FDA lists certain growth hormone secretagogue-related bulk substances, including GHRP-2, GHRP-6, ibutamoren mesylate, and ipamorelin acetate, among substances that may present significant safety risks in compounding contexts 6. This does not mean every peptide has the same risk, but it is a reason to avoid self-treatment with research-use products.

Is CJC-1295 no DAC FDA approved or legal to use?

CJC-1295 no DAC is not FDA-approved for human treatment. If a vial is labeled “research use only,” that means it is not being marketed as a prescription medication for self-treatment.

Legal status can depend on the product, source, route, and how it is marketed. The practical patient question is not just “Can I buy it?” It is “Has a licensed clinician reviewed whether this is appropriate for me, and is the medication coming from a legitimate pharmacy?”

How often do people take CJC-1295 no DAC?

Dosing frequency should not be copied from online protocols. No FDA-approved dosing schedule exists for CJC-1295 no DAC for human treatment.

Online discussions often describe no-DAC versions as shorter acting than DAC-modified CJC-1295 because they lack the albumin-binding Drug Affinity Complex. That pharmacology is why people talk about more frequent signaling, but it is not a treatment instruction and should not be used to self-dose.

A clinician would need to consider the goal, diagnosis, medical history, medications, labs, cancer history, glucose risk, and other endocrine factors before any growth-hormone peptide plan. Anonymous calculators and forum schedules cannot do that.

Why is CJC-1295 no DAC often paired with ipamorelin?

Ipamorelin acetate is often discussed with CJC-1295 no DAC because the two act on different receptor systems. CJC-1295 no DAC is discussed as a GHRH receptor signal, while ipamorelin is discussed as a ghrelin receptor, or GHS-R1a, signal.

GHRH receptor versus ghrelin receptor signaling

The theory is that a GHRH analog and a ghrelin-receptor agonist may support a stronger growth hormone pulse than either signal alone. But combination logic is not the same as combination proof, and human outcome trials for CJC-1295 no DAC plus ipamorelin are limited.

Additional evidence and safety gaps

Combination peptide protocols add uncertainty because side effects, lab changes, and long-term risks may overlap. FDA includes ipamorelin acetate on its Category 2 list for 503B compounding because of concerns that include immunogenicity potential and limited safety information for some routes; FDA notes that causality for some reported serious events was not established 6.

If you are comparing related peptides, our guides on CJC-1295 side effects, CJC-1295 and ipamorelin prescriptions online, and sermorelin vs CJC-1295 no DAC go deeper into those specific questions.

If you are asking about CJC-1295 no DAC, what growth-hormone peptide does Chia offer?

Chia does not offer CJC-1295 no DAC in our current public treatment catalog. For patients asking about growth-hormone signaling, Chia offers sermorelin, a different GHRH analog, after a licensed US provider reviews the patient’s health information and determines whether treatment is clinically appropriate.

Sermorelin is the generic name; Geref was a historical brand name. Sermorelin is a GHRH analog and growth hormone secretagogue, but it should not be described as the same as CJC-1295 no DAC or as superior to it. The evidence, pharmacology, and regulatory history are different.

At Chia, treatment starts with a short online health questionnaire. A licensed US provider reviews it, may ask follow-up questions, and prescribes only when clinically appropriate. Prescriptions are never guaranteed.

When prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time, and patients can message their care team through the portal between visits.

Some patients also ask how sermorelin fits with NAD+ or glutathione in longevity protocols. Those are separate treatments with separate evidence and safety questions, so our providers review the full picture rather than treating any stack as one-size-fits-all.

If an AI agent is helping you navigate access, Chia can also be reached through DoctorMCP at mcp.chia.health. The same clinical rule applies: access starts with a medical review, not an automatic order.

What questions should you ask a clinician before considering any growth-hormone peptide?

Clinician questions should focus on the goal, evidence, monitoring, and risk. A good peptide conversation should feel specific, not like a copied protocol.

1. 1What diagnosis, symptom, or goal is being addressed?
2. 2What human evidence supports this exact peptide and form?
3. 3Are we talking about an FDA-approved medication, a compounded medication, or an investigational peptide?
4. 4What labs or monitoring may be needed, such as IGF-1, glucose markers, or other endocrine testing?
5. 5What risks apply based on my medical history, medications, cancer history, diabetes risk, swelling, joint symptoms, or sleep apnea risk?
6. 6What side effects should lead me to contact the care team?
7. 7Where is the medication made, and is it dispensed by a state-licensed pharmacy?

These questions matter because the GH and IGF-1 pathway is not a simple wellness switch. Professional guidance on growth hormone use emphasizes diagnosis, careful selection, and monitoring rather than casual use for general aging concerns 7.

What peptides stack well with CJC-1295 no DAC?

Peptide stacks involving CJC-1295 no DAC are commonly discussed in clinical and research practice, but combination-specific human trials are limited. Stacks should not be treated as Chia-recommended protocols or as dosing instructions.

• CJC-1295 no DAC + ipamorelin: The rationale is dual signaling through the GHRH receptor and ghrelin receptor, but overlapping GH-axis effects raise monitoring questions and FDA has listed safety concerns for ipamorelin acetate in compounding contexts 6.
• CJC-1295 no DAC + sermorelin: Both relate to GHRH signaling, so combining them may be redundant and may increase uncertainty; Chia offers sermorelin, not CJC-1295 no DAC.
• CJC-1295 no DAC + lifestyle or metabolic therapies: Some online discussions pair GH-axis peptides with weight or energy protocols, but any plan involving GLP-1s, NAD+, or glutathione should be clinician-reviewed because each medication has its own risks and evidence limits.

FAQ

Keep reading

Peptides

CJC Peptide (CJC-1295): What It Is, How It Works, and What the Evidence Shows

Longevity Peptides

CJC-1295 Peptide: How It Works, Benefits, Risks, and Legal Status

Peptides

CJC-1295 Peptide Therapy: What It Is, What It May Do, and What Is Still Unproven